Latest News and Press Releases

ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...

Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....

GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New...

ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...

Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated mid-2024 Completed enrollment of 36 patients required for...

ROCHESTER, N.Y., March 23, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX, “Vaccinex”), a clinical-stage biotechnology company pioneering a differentiated approach to treating...

The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...

Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study...

ROCHESTER, N.Y., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...